January 19, 2018 / 10:47 PM / a month ago

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

Jan 19 (Reuters) - Genmab A/S:

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

* GENMAB - FDA HAS ASSIGNED PDUFA TARGET DATE OF MAY 21, 2018 TO TAKE A DECISION ON DARATUMUMAB IN THE INDICATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below